Specific Killing of HIV-infected Lymphocytes by a Recombinant Immunotoxin Directed against the HIV-1 Envelope Glycoprotein
Open Access
- 1 June 1998
- journal article
- research article
- Published by Springer Nature in Molecular Medicine
- Vol. 4 (6) , 384-391
- https://doi.org/10.1007/bf03401745
Abstract
3B3 is a high-affinity anti-gp120 antibody that neutralizes a wide range of primary and laboratory isolates of HIV-1. The parental antibody was isolated from a combinatorial phage display library constructed from bone marrow RNA of an HIV-infected individual. We have generated a highly active immunotoxin using the 3B3 single-chain Fv (scFv) which can specifically kill lymphocytes infected by HIV-1. We used recombinant DNA technology to clone the Fv fragment of 3B3 and produce a single-chain Fv (scFv). 3B3 scFv was then fused to a truncated version of Pseudomonas exotoxin A (PE38), giving rise to a recombinant immunotoxin 3B3(Fv)-PE38 that was expressed in E. coli and purified to near homogeneity. 3B3(Fv)-PE38 binds with the same affinity as the parental Fab antibody to the MN strain of gp120. The immunotoxin specifically kills a gp120-expressing transfected cell line and a chronically HIV-infected lymphocytic cell line. The immunotoxin is very stable at 37°C, retaining 80% of its original activity after 24 hr. Potent immunotoxins such as 3B3(Fv)-PE38 could be utilized in combination with multidrug cocktails that limit viral replication to help reduce viral reservoirs in patients with AIDS.Keywords
This publication has 30 references indexed in Scilit:
- Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genesPublished by Elsevier ,2004
- Decay characteristics of HIV-1-infected compartments during combination therapyNature, 1997
- Therapeutic potential of anti-HIV immunotoxinsAntiviral Research, 1996
- Engineering antibody Fv fragments for cancer detection and therapy: Bisulfide-stabilized Fv fragmentsNature Biotechnology, 1996
- Recombinant Immunotoxins: From Basic Research to Cancer TherapyMethods, 1995
- Recombinant Toxins: New Therapeutic Agents for CancerAnnals of the New York Academy of Sciences, 1995
- Functional domains of pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coliCell, 1987
- Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)Science, 1983